tiprankstipranks
Trending News
More News >
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Advertisement

Coherus Biosciences (CHRS) AI Stock Analysis

Compare
1,626 Followers

Top Page

CHRS

Coherus Biosciences

(NASDAQ:CHRS)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 4o)
Rating:54Neutral
Price Target:
$1.50
▲(0.00% Upside)
The overall stock score reflects significant financial challenges, with declining revenue and profitability, and negative cash flows weighing heavily. However, strong earnings call highlights and bullish technical indicators provide some positive offset. The valuation remains unattractive due to negative earnings and lack of dividends.
Positive Factors
Revenue Growth
The significant revenue growth of LOQTORZI indicates strong market adoption and potential for continued expansion, supporting long-term revenue streams.
Strategic Repositioning
Focusing on oncology aligns Coherus with high-demand sectors, potentially enhancing its competitive position and long-term growth prospects.
Financial Position
A strong cash position ensures operational stability and the ability to invest in growth opportunities, supporting long-term strategic initiatives.
Negative Factors
Revenue Decline
Declining revenue and profitability highlight operational challenges, potentially impacting the company's ability to sustain growth and market presence.
Cash Flow Challenges
Negative cash flows indicate financial strain, limiting the company's ability to fund operations and invest in growth, impacting long-term viability.
Community Adoption Challenges
Slow community adoption of LOQTORZI may hinder revenue growth and market penetration, affecting the company's competitive edge in the long term.

Coherus Biosciences (CHRS) vs. SPDR S&P 500 ETF (SPY)

Coherus Biosciences Business Overview & Revenue Model

Company DescriptionCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
How the Company Makes MoneyCoherus Biosciences generates revenue primarily through the sale of its biosimilar products. The company has established key partnerships with other pharmaceutical companies to enhance its research and development capabilities and expand its market reach. Significant revenue streams include product sales from its approved biosimilars, royalties from collaborations, and potential milestone payments associated with its pipeline products. Additionally, the company may benefit from expanding its portfolio of biosimilars as it seeks to capture market share in the growing biosimilars market, which is driven by increasing demand for cost-effective biologic therapies.

Coherus Biosciences Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 10, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong focus on revenue growth and strategic repositioning, with significant progress in financial management and pipeline development. However, challenges remain in the adoption of LOQTORZI in community settings and competitive pressures in pipeline development. The positive aspects of revenue growth and strategic alignment outweigh the challenges.
Q2-2025 Updates
Positive Updates
LOQTORZI Revenue Growth
LOQTORZI's net revenue in the second quarter grew 36% over Q1 2025 to $10 million, marking a 65% increase year-over-year.
Improved Financial Position
Coherus Oncology ended Q2 with $238 million in cash and investments, projecting sufficient cash to provide runway through 2026.
Strategic Repositioning as Coherus Oncology
The company has completed its strategic repositioning to focus on oncology, aligning its mission and commercial strategy.
Promising Pipeline Developments
The company highlighted the development of CHS-114 and casdozokitug, noting potential best-in-class attributes and significant market opportunities.
Cost Management and Savings
Achieved additional progress on managing cost structure with expected annual savings of approximately $30 million from headcount reductions.
Negative Updates
Challenges in Community Adoption
While significant progress was made in academic centers, adoption of LOQTORZI in the community setting is slower, requiring more targeted efforts.
Development Competition
The CCR8 Treg depleter class faces vigorous global development competition, posing a challenge to market entry timing.
Company Guidance
During Coherus Oncology's Q2 2025 earnings call, CEO Dennis M. Lanfear provided guidance on the company's strategic focus and anticipated growth. He highlighted the approval and commercial success of their next-generation PD-1 inhibitor, LOQTORZI, which saw a 36% increase in net revenue to $10 million in Q2 2025, driven by physician adoption and updated NCCN guidelines. Lanfear emphasized the potential of their pipeline assets, including CHS-114 and casdozokitug, to expand market opportunities, with second-line head and neck cancer and first-line hepatocellular carcinoma being key focuses. The company projects total 2025 revenues between $40 million and $50 million and maintains a strong balance sheet with $238 million in cash, ensuring operations through 2026.

Coherus Biosciences Financial Statement Overview

Summary
Coherus Biosciences faces substantial financial challenges with declining revenues, persistent losses, and high leverage. The negative equity position and reliance on financing highlight potential risks. Improvement in operational performance and financial stability is critical for future growth.
Income Statement
35
Negative
The income statement reveals significant challenges for Coherus Biosciences, with declining revenue and consistent net losses over the periods. The TTM data shows negative margins across gross profit, EBIT, and EBITDA, indicating profitability issues. Revenue growth is negative, reflecting a downward trend in sales.
Balance Sheet
40
Negative
The balance sheet indicates high financial leverage with a negative stockholders' equity, suggesting insolvency risks. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is negative, underscoring financial instability. Overall, the balance sheet reflects potential risks due to high liabilities.
Cash Flow
30
Negative
Cash flow analysis shows limited operational cash generation with a marginally positive free cash flow in the TTM period. However, historical data reflects negative operating and free cash flows, indicating reliance on external financing. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue142.77M266.96M257.24M211.04M326.55M475.82M
Gross Profit81.11M149.41M98.25M140.96M268.96M438.16M
EBITDA-137.84M60.94M-193.94M-255.58M-260.69M161.84M
Net Income179.75M28.51M-237.89M-291.75M-287.10M132.24M
Balance Sheet
Total Assets439.46M448.53M629.60M480.85M679.33M841.65M
Cash, Cash Equivalents and Short-Term Investments237.64M125.99M117.75M191.68M417.19M541.16M
Total Debt2.41M269.90M480.84M480.42M419.02M417.10M
Total Liabilities319.64M580.52M823.03M618.26M581.61M560.67M
Stockholders Equity119.83M-131.99M-193.43M-137.42M97.73M280.97M
Cash Flow
Free Cash Flow-105.87M-20.44M-175.17M-243.16M-38.72M147.09M
Operating Cash Flow-105.87M-20.44M-174.88M-241.12M-37.43M154.15M
Investing Cash Flow445.05M230.32M144.64M-166.85M-138.41M-14.40M
Financing Cash Flow-281.72M-186.97M69.60M54.33M51.88M223.95M

Coherus Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.50
Price Trends
50DMA
1.15
Positive
100DMA
0.98
Positive
200DMA
1.08
Positive
Market Momentum
MACD
0.11
Negative
RSI
62.14
Neutral
STOCH
60.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Positive. The current price of 1.5 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.15, and above the 200-day MA of 1.08, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 62.14 is Neutral, neither overbought nor oversold. The STOCH value of 60.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRS.

Coherus Biosciences Risk Analysis

Coherus Biosciences disclosed 68 risk factors in its most recent earnings report. Coherus Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Coherus Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$174.34M5.55-860.65%-53.67%-330.15%
49
Neutral
$158.65M-4.90-113.68%-100.00%11.41%
43
Neutral
$171.63M-4.9664.43%
41
Neutral
$104.68M-1.596.27%
34
Underperform
$114.29M-1.3129.72%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CHRS
Coherus Biosciences
1.50
0.46
44.23%
SLS
SELLAS Life Sciences Group
1.63
0.38
30.40%
XBIT
XBiotech
2.70
-5.03
-65.07%
NAUT
Nautilus Biotechnolgy
0.83
-2.02
-70.88%
TIL
Instil Bio
16.93
-50.39
-74.85%
GNLX
Genelux Corp.
4.20
1.83
77.22%

Coherus Biosciences Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Coherus Biosciences Regains Nasdaq Compliance
Positive
Sep 8, 2025

On June 30, 2025, Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its stock price falling below $1.00 per share for 30 consecutive business days. By September 5, 2025, the company regained compliance with Nasdaq’s listing requirements, ensuring its continued presence on the Nasdaq Global Market.

Delistings and Listing ChangesRegulatory Filings and Compliance
Coherus Biosciences Receives Nasdaq Deficiency Notice
Negative
Jul 3, 2025

On June 30, 2025, Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days, which is below the required minimum for continued listing. The company has until December 29, 2025, to regain compliance by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive business days. If Coherus fails to meet this requirement, it may seek an additional compliance period or face potential delisting, with options to appeal any delisting determination.

Executive/Board ChangesShareholder Meetings
Coherus Biosciences Holds Virtual Annual Stockholder Meeting
Neutral
Jun 13, 2025

On June 11, 2025, Coherus Oncology, Inc. held its Annual Meeting of Stockholders virtually, where various proposals were voted on. The stockholders elected three Class II directors, ratified Ernst & Young LLP as the company’s accounting firm, approved executive compensation, and amended the 2014 Employee Stock Purchase Plan.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025